LOS GATOS, Calif., Oct. 22 TriCipher today joined theSAFE(TM) (Signatures and Authentication for Everyone) BioPharma AssociationVendor Partner Program, pledging to promote the adoption of the SAFE standardsthrough the company's user and transaction authentication solutions.SAFE-approved credentials will seamlessly operate on TriCipher ArmoredCredential System (TACS), the company's strong authentication platformleveraging a variety of multi-factor credentials.
The industry group gives TriCipher access to forward-thinking corporateusers of digital information processing, such as Amgen, AstraZeneca,Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Johnson & Johnson, Merck,Pfizer, Procter & Gamble, Roche and Sanofi-Aventis. By agreeing tocredentialing standards, these companies reduce the cost and time forpharmaceutical companies to advance drug development and deploy new businessprocesses.
SAFE provides the industry's legal foundation for digital signatures anduser authentication across pharmaceutical companies. Its standards arelegally enforceable because they ensure user authentication, digital documentintegrity and auditable non-repudiation of users' actions.
"The pharmaceutical industry sets the bar for other industries with highlyregulated and valuable online activities," said John De Santis, TriCipher'sCEO. "SAFE and TriCipher make it possible to get more business value out ofstrong authentication credentials, increasing profits and better servingcustomers with faster product development and lower costs."
TriCipher, Inc. provides a unified authentication infrastructure toprotect web and enterprise portals, the people that use them and the businessprocess that flows through them against fraud and identity theft. TheTriCipher Armored Credential System(TM) (TACS) is the first authenticationsystem that enables companies to deploy and manage multiple types ofcredentials from a single infrastructure. Through this flexible"Authentication Ladder," TriCipher protects customer investment by adjustingauthentication strength to defeat new threats and to meet regulatory changeswithout the need to implement a new infrastructure. Founded in 2000, TriCipheris headquartered in Los Gatos, Calif. The company is funded by ArrowPathVenture Capital, Intel Capital, RBC Technology Ventures, Trident Capital, andWasatch Venture Fund. For more information, visit TriCipher on the web athttp://www.tricipher.com
About SAFE-BioPharma Association
SAFE-BioPharma Association is the non-profit association that created andmanages the SAFE(TM) digital identity and digital signature standard for thepharmaceutical and healthcare industries. Through the SAFE standard, theassociation promotes interoperability and integration among researchers,vendors, regulators, clinicians and other pharmaceutical and healthcarestakeholders. The SAFE standard provides a secure, enforceable, and regulatorycompliant way to verify the identities of parties involved in business-to-business and business-to-regulator electronic transactions. SAFE stands for"Signatures and Authentication For Everyone." The Association's membersinclude Amgen, AstraZeneca, Bristol-Myers Squibb, Genzyme, GlaxoSmithKline,Johnson & Johnson, Merck, Pfizer, Procter & Gamble, Roche and Sanofi-Aventis.For more information visit http://www.safe-biopharma.org.
SAFE(TM) is a trademark of SAFE-BioPharma Association. Any use of thistrademark requires approval from SAFE-BioPharma Association.
SOURCE TriCipher, Inc.